Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 811 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: SARS Pneumonia Clear all
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

KIDney Injury in Times of COVID-19 (KIDCOV)

NCT04705766
View directory record Official record
Conditions
SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Interventions
Urine Collection
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 24, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

NCT04476953
View directory record Official record
Conditions
Covid19
Interventions
Placebo, Fisetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons

NCT04799392
View directory record Official record
Conditions
COVID-19, SARS-CoV-2, Coronavirus
Interventions
NOWDx COVID-19 Test
Device
Lead sponsor
NOWDiagnostics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
5
States / cities
Fayetteville, Arkansas • Anoka, Minnesota • Nixa, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Treatment for COVID-19 in High-Risk Adult Outpatients

NCT04354428
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
6
States / cities
Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 24, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Testing Sample Acquisition Throughput and Efficiency

NCT04532411
View directory record Official record
Conditions
SARS-CoV Infection, Respiratory Viral Infection, Personal Protective Equipment, Covid19
Interventions
Personal Protective Testing Booth
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
28,948 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

AT1001 for the Treatment of Long COVID

NCT05747534
View directory record Official record
Conditions
Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 50 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 24, 2026, 9:22 AM EDT
Not yet recruiting Phase 2 Interventional

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

NCT07597902
View directory record Official record
Conditions
Post-acute Sequelae of COVID-19, Long COVID
Interventions
Valacyclovir, Celecoxib, Paxlovid, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients

NCT05077969
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 24, 2026, 9:22 AM EDT
No Longer Available No phase listed Expanded access

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

NCT05235347
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
4
States / cities
Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 24, 2026, 9:22 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

NCT04412252
View directory record Official record
Conditions
COVID-19
Interventions
Tofacitinib, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Hartford, Connecticut • Iowa City, Iowa • Shreveport, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2020 · Synced Oct 24, 2026, 9:22 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients

NCT04950673
View directory record Official record
Conditions
Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome, COVID Long-Haul
Interventions
Cognivue
Device
Lead sponsor
Cognivue, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Irvine, California • Visalia, California • Boca Raton, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

A Study of the GRIP Influenza and SARS-CoV-2 POC Assays

NCT05674370
View directory record Official record
Conditions
COVID-19, Influenza
Interventions
GRIP Electronic Diagnostic Chip, Laboratory-based nucleic acid amplification tests (NAATs)
Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 24, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 SARS-CoV-2 RAST Study

NCT06452056
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Rapid Antigen Screening Test
Device
Lead sponsor
Columbia University
Other
Eligibility
2 Years and older
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 24, 2026, 9:22 AM EDT
Completed No phase listed Observational

Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic

NCT04374656
View directory record Official record
Conditions
Conjunctivitis, SARS-CoV-2, COVID-19, Ocular Infection, Viral, Ocular Inflammation
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants

NCT05260437
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg), CV2CoV (12 µg), CV2CoV (16 µg), CV2CoV (20 µg)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
24
States / cities
Aurora, Colorado • Hallandale, Florida • Lakeland, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 24, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

NCT04466683
View directory record Official record
Conditions
Covid-19, Sars-CoV2, Pneumonia
Interventions
Low dose radiation 35 cGy, High dose radiation 100 cGy
Radiation
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Boca Raton, Florida • Miami, Florida • Maywood, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 9:22 AM EDT
Completed Phase 4 Interventional Results available

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

NCT04969250
View directory record Official record
Conditions
Covid19
Interventions
Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 24, 2026, 9:22 AM EDT
Not listed Phase 3 Interventional

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19

NCT04334382
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
45 Years and older
Enrollment
1,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

NCT04605588
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
Nitazoxanide, Placebo Nitazoxanide, Ribavirin, Placebo Ribavirin, Hydroxychloroquine, Placebo Hydroxychloroquine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 24, 2026, 9:22 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07536308
View directory record Official record
Conditions
COVID-19
Interventions
OCU500
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
6
States / cities
Decatur, Georgia • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 9:22 AM EDT
Recruiting No phase listed Observational

COVID-19 Coagulopathy Extension Study

NCT05334615
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 24, 2026, 9:22 AM EDT
Terminated Phase 3 Interventional Results available

Azithromycin for COVID-19 Treatment in Outpatients Nationwide

NCT04332107
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Azithromycin, Placebos
Drug
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 24, 2026, 9:22 AM EDT